NCT02792257View on ClinicalTrials.gov

Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Alzheimer's Disease
Interventions
DRUG

Dronabinol (Marinol®)

5mg - 10mg daily dose

DRUG

Placebo

Daily dose

Trial Locations (5)

21224

Johns Hopkins University, Baltimore

33137

Miami Jewish Health, Miami

02478

McLean Hospital, Belmont

02111

Tufts Medical Center, Boston

01970

North Shore Medical Center, Salem

All Listed Sponsors
collaborator

Mclean Hospital

OTHER

collaborator

Miami Jewish Health

UNKNOWN

collaborator

National Institute on Aging (NIA)

NIH

collaborator

Tufts Medical Center

OTHER

lead

Johns Hopkins University

OTHER

NCT02792257 - Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease | Biotech Hunter | Biotech Hunter